Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-target Mendelian randomisation applied to metabolic dysfunction-associated steatotic liver disease: opportunities and challenges

1 Oct 2024

Abstract excerpt

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent cause of chronic liver disease worldwide affecting over one-third of the adult population. Despite the recent evolution of new nomenclature and diagnostic criteria for MASLD, progress in drug development for this condition remains limited. This review highlights the potential of drug-target Mendelian randomisation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Associations and Epidemiology
Share to Lipid metabolism and disorders
Share to Liver Disease Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39944268
DOI: 10.1136/egastro-2024-100114

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-target Mendelian randomisation applied to metabolic dysfunction-associated steatotic liver disease: opportunities and challengesPMID 39944268Read ↗

Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical applicationSemantic proximity Read ↗

Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update.Semantic proximity Read ↗

Common pitfalls in drug target Mendelian randomization and how to avoid them.Semantic proximity Read ↗

Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease?Semantic proximity Read ↗

High salt diet causally increases metabolic dysfunction-associated steatotic liver disease risk: A bidirectional mendelian randomization study.Semantic proximity Read ↗

Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver DiseaseSemantic proximity Read ↗

Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisationSemantic proximity Read ↗

Evaluation of Human Hepatocyte Drug Metabolism Carrying High-Risk or Protection-Associated Liver Disease Genetic VariantsSemantic proximity Read ↗

Diagnostic Uptake of Targeted Sequencing in Adults With Steatotic Liver Disease and a Suspected Genetic Contribution.Semantic proximity Read ↗

Novel Insights into the Relationship Between Glucose-Lowering Drugs and Nonalcoholic Fatty Liver Disease and liver function: a Mendelian Randomization StudySemantic proximity Read ↗

Novel genetic insights into the roles of amino acids in metabolic dysfunction-associated steatotic liver diseaseSemantic proximity Read ↗

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.